Jun 27 |
BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?
|
Jun 18 |
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
|
Jun 6 |
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
|
Jun 5 |
The 3 Best Biotech Stocks to Buy in June 2024
|
Jun 4 |
BridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug
|
Jun 4 |
BridgeBio releases new phase 2 results for infigratinib for achondroplasia
|
Jun 4 |
BridgeBio data show sustained benefit for achondroplasia drug
|
Jun 4 |
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
|
Jun 3 |
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
|
Jun 3 |
BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)
|